Lesions of the Inferior Olive in Cases of Autoimmune GFAP Astrocytopathy: A Case Series Report - Top-Institutions - MDSpire

Lesions of the Inferior Olive in Cases of Autoimmune GFAP Astrocytopathy: A Case Series Report

  • By

  • Haruka Kuwashige

  • Atsuhiko Sugiyama

  • Shinji Aoyama

  • Hideo Handa

  • Mitsuyoshi Tamura

  • Hiroki Masuda

  • Yuki Nakagawa

  • Masahiro Namiki

  • Hajime Yokota

  • Hiroki Mukai

  • Akio Kimura

  • Takayoshi Shimohata

  • Masahiro Mori

  • January 31, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Neuroinflammation

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Neuroinfectious Diseases

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Neuroradiology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neuroimmunology
    • Autoimmune Neurology

Original Source(s)

Lesions of the Inferior Olive in Cases of Autoimmune GFAP Astrocytopathy: A Case Series Report

  • by Haruka Kuwashige, Atsuhiko Sugiyama, Shinji Aoyama, Hideo Handa, Mitsuyoshi Tamura, Hiroki Masuda, Yuki Nakagawa, Masahiro Namiki, Hajime Yokota, Hiroki Mukai, Akio Kimura, Takayoshi Shimohata, Masahiro Mori

  • January 31, 2026

Related Content

First Report of Neuroinvasive West Nile Virus Cases in the Istanbul Region During 2019

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.